Neuland Laboratories Ltd.

As of June 30, 2026, Neuland Laboratories Ltd. carries a market capitalization of 238.37B, placing it among publicly traded companies globally. Its enterprise value stands at 238.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neuland Laboratories Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Neuland Laboratories Ltd. has 12.83M shares outstanding.

As of June 30, 2026, Neuland Laboratories Ltd. trades at a trailing price-to-earnings ratio of 47.89.

As of June 30, 2026, Neuland Laboratories Ltd. trades at an EV/EBITDA multiple of 31.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 35.86 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 238.37B versus a market cap of 238.37B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.60M in revenue per employee across its workforce of 3,592.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Neuland Laboratories Ltd. recorded 1.71B in income tax expense. That works out to an effective tax rate of 25.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.69B, leaving 4.98B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Neuland Laboratories Ltd.'s stock has gained approximately 16.40% over the past 52 weeks. The 50-day moving average sits at 22,205.72, while the 200-day moving average is 17,266.79.

Over the twelve months ended June 30, 2026, Neuland Laboratories Ltd. generated 23.72B in revenue and converted that into 4.98B in net income, yielding earnings per share of 387.97. EBITDA reached 7.63B, while operating income came in at 6.65B.

Over the twelve months ended June 30, 2026, Neuland Laboratories Ltd. posted a gross margin of 55.18, reflecting its pricing power and cost economics. The operating margin of 28.03 and net profit margin of 20.99 provide insight into operational efficiency.

Neuland Laboratories Ltd.'s most recent stock split took place on August 13, 2014 with a 580:607 split ratio.